Medtronic (MDT) vs. Its Peers Critical Review

Medtronic (NYSE:MDT – Get Free Report) is one of 510 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its rivals? We will compare Medtronic to similar companies based on the strength of its earnings, institutional ownership, risk, valuation, profitability, analyst recommendations and dividends.

Profitability

This table compares Medtronic and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Medtronic 13.93% 14.78% 7.97%
Medtronic Competitors -191.42% -197.86% -21.83%

Dividends

Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 2.9%. Medtronic pays out 70.9% of its earnings in the form of a dividend. As a group, “Healthcare Equipment & Supplies” companies pay a dividend yield of 2.1% and pay out 40.8% of their earnings in the form of a dividend. Medtronic has increased its dividend for 49 consecutive years.

Analyst Ratings

This is a breakdown of recent ratings for Medtronic and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medtronic 1 8 18 0 2.63
Medtronic Competitors 4330 10559 18358 840 2.46

Medtronic presently has a consensus price target of $104.17, indicating a potential upside of 4.30%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 29.11%. Given Medtronic’s rivals higher probable upside, analysts plainly believe Medtronic has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Medtronic and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Medtronic $36.36 billion $4.80 billion 24.60
Medtronic Competitors $1.89 billion $137.31 million 5.94

Medtronic has higher revenue and earnings than its rivals. Medtronic is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Medtronic has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Medtronic’s rivals have a beta of 2.57, meaning that their average stock price is 157% more volatile than the S&P 500.

Institutional and Insider Ownership

82.1% of Medtronic shares are held by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 0.3% of Medtronic shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Medtronic beats its rivals on 10 of the 15 factors compared.

Medtronic Company Profile

(Get Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.